Cancer Care Ontario | Cancer Care Ontario

You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.

Skip to main content Skip to search

128 Results

Guidelines and Advice

Use of Amifostine to Ameliorate the Toxic Effects of Chemotherapy in the Treatment of Cancer

Status: Archived
ID: 12-6

May 2012

Guidelines and Advice

Use of Gemcitabine in the Treatment of Advanced Pancreatic Adenocarcinoma

Status: Archived
ID: 2-10

Sep 2011

Guidelines and Advice

Use of Continuous Infusion Pumps During Radiation Treatment: Recommendation Report (March 2012)

Status: Current
ID: GL-C50-29

Mar 2012

Guidelines and Advice

Use of Irinotecan in the Second-Line Treatment of Metastatic Colorectal Cancer

Status: Archived
ID: 2-16

Sep 2011

Guidelines and Advice

Dasatinib for the Treatment of Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia

Status: Archived
ID: 6-23 (CED)

Jan 2012

Guidelines and Advice

Dose Objectives for Head and Neck IMRT Treatment Planning - Recommendation Report

Status: Current
ID: GL-C50-13

Feb 2014

Guidelines and Advice

Doxorubicin-Based Chemotherapy for the Palliative Treatment of Adult Patients with Locally Advanced or Metastatic Soft Tissue Sarcoma

Status: Archived
ID: 11-1
Version: 2

Oct 2014

Guidelines and Advice

Use of the Epidermal Growth Factor Receptor Inhibitors Gefitinib (Iressa®), Erlotinib (Tarceva®), Afatinib, Dacomitinib or Icotinib in the Treatment of Non–SmallCell Lung Cancer: A Clinical Practice Guideline

Status: In-Review
ID: 7-9
Version: 2

Apr 2014

Drug Funding Frequently Asked Questions

We’ve compiled the answers to many commonly asked questions about cancer drug costs and funding in Ontario.

Symptom Management

Urinary Incontinence - Prostate Cancer

Symptom Management

Urinary Problems - Prostate Cancer

Drug

dexamethasone

Quick Link(s):

Patient Info Sheet

Jan 2018

Pages